key: cord-0760651-0bekqjmm authors: George, S.; Pal, A. C.; Gagnon, J.; Timalsina, S.; Singh, P.; Vydyam, P.; Munshi, M.; Chiu, J. E.; Renard, I.; Harden, C. A.; Ott, I. M.; Watkins, A. E.; Vogels, C. B. F.; Lu, P.; Tokuyama, M.; Venkataraman, A.; Casanovas-Massana, A.; Wyllie, A. L.; Rao, V.; Campbell, M.; Farhadian, S. F.; Grubaugh, N. D.; Dela Cruz, C. S.; Ko, A. I.; Perez, A. B.; Akaho, E. H.; Moledina, D. G.; Testani, J.; John, A. R.; Ledizet, M.; Mamoun, C. B. title: Evidence for SARS-CoV-2 Spike Protein in the Urine of COVID-19 patients date: 2021-01-31 journal: nan DOI: 10.1101/2021.01.27.21250637 sha: 889a488db8897f0d128ac8905369f10c6b7818b8 doc_id: 760651 cord_uid: 0bekqjmm SARS-CoV-2 infection has so far affected over 42 million people worldwide, causing over 1.1 million deaths. With the large majority of SARS-CoV-2 infected individuals being asymptomatic, major concerns have been raised about possible long-term consequences of the infection. We developed an antigen capture assay to detect SARS-CoV-2 spike protein in urine samples from COVID-19 patients whose diagnosis was confirmed by PCR from nasopharyngeal swabs (NP-PCR+). The study used a collection of 233 urine samples from 132 participants from Yale New Haven Hospital and the Childrens Hospital of Philadelphia obtained during the pandemic (106 NP-PCR+ and 26 NP-PCR-) as well as a collection of 20 urine samples from 20 individuals collected before the pandemic. Our analysis identified 23 out of 91 (25%) NP-PCR+ adult participants with SARS-CoV-2 spike S1 protein in urine (Ur-S+). Interestingly, although all NP-PCR+ children were Ur-S-, 1 NP-PCR- child was found to be positive for spike protein in urine. Of the 23 Ur-S+ adults, only 1 individual showed detectable viral RNA in urine. Our analysis further showed that 24% and 21% of NP-PCR+ adults have high levels of albumin and cystatin C in urine, respectively. Among individuals with albuminuria (>0.3 mg/mg of creatinine) statistical correlation could be found between albumin and spike protein in urine. Together, our data showed that 1 of 4 of SARS-CoV-2 infected individuals develop renal abnormalities such as albuminuria. Awareness about the long-term impact of these findings is warranted. December 31, 2019 will be remembered in the history of humanity and the annals of medicine, epidemiology and global health as the D-day of the ongoing coronavirus pandemic. It is the day when health authorities in Wuhan city, China reported a cluster of patients with symptoms of unidentified pneumonia, with characteristics reminiscent of viral pneumonia. [1] [2] [3] [4] By March 12, 2020, the disease spread across the globe with 145,200 cases, leading the World Health Organization to declare COVID-19 a global pandemic. 5 As of mid-January 2021, more than 96 million cases and over 2 million deaths have been recorded worldwide. Epidemiological estimates suggest that approximately 70% of the world's population could become infected with COVID-19, with global case fatality rate between 0.1% and over 25%. 6 Coronavirus-related illnesses in humans are caused by seven viruses, four of which (HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1) cause common cold SARS-CoV-2, the agent of COVID-19 pandemic, is a member of betacoranaviruses, which mostly infect bats. 9 However, this enveloped, positive-stranded RNA virus is also capable of infecting humans. 10 Genetic characterization of SARS-CoV-2 shows it is closely related to bat virus RaTG13. 11 Similar to the extensively studied SARS-CoV, 12, 13 the spike (S) protein of the SARS-CoV-2 plays a crucial role in viral attachment to the human cell surface All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint membrane angiotensin-converting enzyme 2 (ACE2) receptor and entry into the target cell. 14, 15 This process is accompanied by proteolytically activating the SARS-CoV-2 spike protein at the S1/S2 site, by cleaving S1 from S2 protein by host proteases. 15 Therefore, screening for SARS-CoV-2 spike protein could be an excellent strategy to monitor active and recent COVID-19 infections. Analysis of the tissue distribution of ACE2 showed high expression of the receptor in the epithelial cells of intestine, renal, alveolar, heart, artery, and gastrointestinal system, 16 suggesting that in addition to the lungs and the upper respiratory tract, SARS-CoV-2 could also invade other important organs including the kidneys and cause inflammation with possibly long lasting injuries. 17 To date, the impact of SARS-CoV-2 infection on renal function has been controversial. Analysis of a cohort of 193 adult patients with laboratory confirmed SARS-CoV-2 infection from 3 hospitals in and around Wuhan, China showed kidney abnormalities (CT scan) with 63% of the participants showing proteinuria. 18 In the USA, a study by Hirsch et al., showed that 37% of COVID-19 patients developed Acute Kidney Infection (AKI) during hospitalization, most of whom were on mechanical ventilation. 19 However, another study by Wang et al., on 116 COVID-19 confirmed patients from Renmin Hospital in Wuhan, China found that AKI was uncommon, and that SARS-CoV-2 infection did not result in AKI or exacerbate Chronic Kidney Disease. 20 Although these studies focused on the presence of specific biomarkers of kidney injury, analysis of urine for the presence of SARS-CoV-2 proteins in COVID-19 patients or asymptomatic individuals have not been examined heretofore. In this study, we developed an antigen capture assay that detects the presence of SARS-CoV-2 spike protein in biological specimens and used it to evaluate the 6 presence of the antigen in urine samples from nasopharyngeal (NP) PCR positive (NP-PCR+) and negative (NP-PCR-) adults and children collected during the COVID-19 pandemic. Our study population also included urine samples collected 3 to 5 years prior to the pandemic. We found that in our study population, 25.2% of adult COVID-19 patients had SARS-CoV-2 spike S1 protein in their urine at least once during the course of infection. Urine protein analyses further revealed proteinuria with elevated albumin and cystatin C in 24% and 21% of NP-PCR+ individuals, respectively. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A urine sample was considered positive for SARS-CoV-2 spike protein if the optical density (OD) value obtained was greater than the OD value obtained by COVID-19 NP-PCR-urine sample spiked with 5ng/mL SARS-CoV-2 spike protein. Levels of SARS-CoV-2 spike protein, albumin and cystatin C in urine were normalized to urine creatinine levels and expressed as mg/mg of urine creatinine. 21, 22 The fractional excretion of sodium (FENa) was calculated using the formula 23-25 The FEUrea was calculated using the formula 23-25 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were served as controls. These samples were collected between 2015 -2018. Convenience sampling technique was adopted where no statistical methods were used to predetermine sample size. A flowchart describing the study population is shown in Figure 1A . Sample processing, RNA extraction and qPCR detection. Urine samples were centrifuged at 2000 RCF for 10 min at room temperature and immediately used for RNA extraction or stored frozen at -80˚C. RNA extraction and RT-qPCR detection for SARS-CoV-2 in urine followed the procedures detailed in reference. 26 From CHOP, all urine samples were treated with NP40 for viral inactivation prior to shipping to Yale School of Medicine. Our comparative analysis using Capture ELISA on urine samples from NP40 treated and non-treated samples, revealed no-effect of NP40 on the assay sensitivity. Detection of SARS-CoV-2 spike protein using Urine Capture ELISA (U ELISA ) and Rabbit polyclonal anti-spike protein antibody purified using Protein G immunoaffinity chromatography was purchased from MyBioSource (MBS434243; 2µg/µL) and used as capture antibody in the capture ELISA. This antibody was also biotinylated using EZ-Link™ Micro Sulfo-NHS-Biotinylation Kit (ThermoFisher; Cat No 21925) and used as detection antibody. In addition, SARS-CoV-2 spike protein S1 (78. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint 1B). For the urine capture ELISA (U ELISA ), urine samples from participants who were NP-PCR-were spiked with different concentrations of SARS-CoV-2 S1 protein (500ng/100µL; 250ng/100µL; 100ng/100µL; 50ng/100µL; 25ng/100µL; 10ng/100µL; 5ng/100µL; 0.5ng/100µL and 0.05ng/100µL; Figure 1C ) and used as a standard in every plate. For the serum capture ELISA (S ELISA ), human serum sample from a healthy individual was spiked with different concentrations of SARS-CoV-2 S1 protein (500ng/100µL; 250ng/100µL; 100ng/100µL; 50ng/100µL; 25ng/100µL; 10ng/100µL; 5ng/100µL; and 0.5ng/100µL; Figure S4 ). A 96 ELISA well-plate (Nunc MaxiSorp Plate; ThermoFisher Cat No 442404) was coated with 5µg/mL polyclonal anti-spike antibody diluted in carbonate coating buffer (0.848g Na 2 CO 3 , 1.428g NaHCO 3, 500mL distilled water) and incubated at room temperature for 2 hours. Unbound antibodies were removed, and 300µL of blocking solution (PBS 0.05% Tween-20 (PBST)-2%BSA) was added per well. The plate was then incubated for an hour at room temperature. In case of U ELISA , this was followed by an addition of 100µL of urine sample per well to screen for the presence of SARS-CoV-2 spike protein and the plate was incubated over night at 4ºC. In case of S ELISA , this was followed by the addition of 20µL of serum sample and 80µL of PBS per well to screen for the presence of SARS-CoV-2 spike protein and the plate was incubated over night at 4ºC. After 15-16 hours, the wells were washed four times with PBST, biotinylated polyclonal anti-COVID-19 antibodies (spike protein) were added at a concentration of 5µg/mL, and plates were incubated for 1 hour at room temperature. After four washes with PBST, HRP-streptavidin conjugate (Seracare Life Sciences INC; Cat No KPL 474-3000) was added at a dilution of 1:10000 in PBST, and plates were incubated for 1 hour at room temperature. A final wash (4X) with PBST was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1B . In addition, to determine the specificity of polyclonal SARS-CoV-2 anti-spike antibodies (MyBioSource; MBS434243; 2µg/µL), different concentrations (0.1µg, 0.5µg and 1µg) of purified recombinant SARS-CoV-2 S1 (GenScript; Cat No Z03501) were probed using a Western blot ( Figure 1E ). No 70037425) were obtained from BEI Resources, NIAID, NIH. These proteins were used to spike NP-PCR-urine sample at 5µg/mL and 5ng/mL in the urine capture ELISA. In addition, two NP-PCR+ urine samples were spiked with SARS-CoV-2 Spike (S1) protein at the same concentrations as stated above. The cross-reactivity of polyclonal anti-spike antibody was measured in optical density (OD) at 450nm. Urine electrolytes were measured using ion sensitive electrodes on the Randox Imola clinical chemistry analyzer (Randox Laboratories, Ireland, UK). Urine creatinine was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint determined using a modified Jaffe method. Creatinine measurements are standardized to National Institute of Standards and Technology reference material (SRM 967). Cystatin C and microalbumin were used in accordance with the manufacturer's instructions (Randox Laboratories, Crumlin, UK). To determine the integrity of SARS-CoV-2 spike protein in urine, 10µL urine Statistical analyses were performed using a two-tailed unpaired Student's t-test or oneway Analysis of Variance (ANOVA) in case of multiple variables. Categorical variables All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint are expressed as numbers (%). Differences were considered statistically significant when p < 0.05. Table 1 ), we developed a capture ELISA using antispike polyclonal antibodies for antigen capture and biotinylated antibodies for detection of the antigen-antibody complex ( Figure 1B ). In order to use this sandwich ELISA for detection of SARS-CoV-2 spike protein in a collection of urine samples, the assay was optimized using purified recombinant S1 antigen in PBS (data not shown) and urine samples from confirmed NP-PCR SARS-CoV-2 negative individuals and standard curves were generated ( Figure 1C ). Using this assay, we determined the lower limit of detection (LOD) to be 5 ng/mL of urine ( Figure 1C ). The specificity of the antibodies was further evaluated by ELISA using available recombinant spike proteins from SARS-CoV and HCoV-HKU1. While no cross-reactivity could be detected with HCoV-HKU1 spike protein at concentrations as high as 5 µg/mL or with SARS-CoV spike protein at 5 ng/mL, a weak signal could be All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint detected by ELISA with SARS-CoV spike protein at 5 µg/mL ( Figure 1D ). Western blot analysis confirmed the specificity of the antibodies towards SARS-CoV-2 spike protein ( Figure 1E ). Having determined the sensitivity and specificity, the assay was then used to examine a repository of 253 urine samples collected from 152 participants for the presence of SARS-CoV-2 spike protein ( Figure 1A ; Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint gender of the COVID-19 patient could be found (P=0.34; Figure 2B ) among 20 of the 23 participants with SARS-CoV-2 spike protein in their urine (information on gender for three individuals was not available). Similarly, no significant association between the presence of the SARS-CoV-2 spike protein and factors such as body mass index (BMI; P=0.16), age (P=0.29) and duration of hospitalization (P=0.49) could be found ( Figure 2C ). In this cohort, we also examined possible correlations between the levels of albumin and cystatin C in the urine samples and BMI, age and duration of hospitalization of the patient. However, no significant association was observed between these confounding factors and elevated levels of albumin (BMI P=0.33, age P=0.058, duration of hospitalization P=0.12) and cystatin C (BMI P=0.36, age P=0.88, duration of hospitalization P=0.11) ( Figure S3A and S3B). Of the 23 COVID-19 patients with spike protein in their urine, 17 provided at least two urine samples during the course of hospitalization ( Figure 3A ). SARS-CoV-2 spike protein could be detected in urine from day 1 to day 44 post-hospital admission ( Figure 3A ). However, no correlation could be found between the concentration of SARS-CoV-2 spike protein in the urine and the day urine sample was collected post hospital admission. To assess whether the presence of spike protein in the urine of a subset of COVID-19 positive individuals is due to the presence SARS-CoV-2 infected cells in this biospecimen, qRT-PCR analysis was conducted on all urine samples from NP-PCR+ individuals using two primer pairs as previously reported. 26 Out of 93 NP-PCR+ patients, only 2 individuals were positive for viral RNA in urine (~2%; Figure 3B ). Of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. Figure 4D ). Previous studies have demonstrated increased level of blood creatinine (>0.3 mg/dL) in individuals with AKI. [28] [29] [30] To determine whether the presence of spike protein in urine was due to AKI, we measured the concentration of creatinine (mg/dL) in sera of individuals that are either positive or negative for spike protein in urine. No significant difference was found between the levels of serum creatinine and the presence or absence of SARS-CoV-2 spike protein in urine among these individuals (P=0.70; Figure S1B ). Among individuals with spike protein in urine, the concentration of serum All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Considering the importance of protein size in renal filtration, we used anti-SARS-CoV-2 spike polyclonal antibodies to detect the protein in urine samples by Western blot. As shown in Figure 3C , a band of 78.3 kDa that comigrates with recombinant S1 antigen could be detected in the urine of spike positive SARS-CoV-2 adults. No S1 protein could be detected in the Ur-S-SARS-CoV-2 positive adults, health care workers or individuals whose urine samples were collected prior to the pandemic. To assess whether the presence of high levels of SARS-CoV-2 Spike protein in the urine samples from COVID-19 patients may be due to the presence of the protein at high levels in serum, we screened 49 available serum samples from the cohort of 38 COVID-19 patients using spike capture ELISA assay (S ELISA ) (48 urine samples; N=38). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint Only 4 samples from 3 individuals showed levels of spike protein in serum above the lower limit of detection (5ng/ml) and none of these were positive in the ELISA assay performed on the urine samples from COVID-19 patients ( Figure 5 ). Together these data suggest that no correlation exists between high levels of spike protein in urine and their serum concentrations. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this study, we developed an antigen capture ELISA assay to detect SARS-CoV-2 spike protein and used it to analyze urine samples from a cohort of 152 individuals, including SARS-CoV-2 NP-PCR+ adults and children. While antigen-based detection assays have been reported, 31, 32 to the best of our knowledge this is the first report of the use of an antigen capture assay to detect spike protein in the urine of SARS-CoV-2 patients and asymptomatic individuals. Chu et al. suggested that the development of AKI in SARS-CoV patients was likely to be due to multi-organ failure rather than kidney tropism of the virus. 33 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Interestingly, our analysis of the urine samples by Western blot showed the presence of the expected size (78.3kDa) of the S1 fragment of the spike protein ( Figure 3C ). In addition, we also observed additional fragments, suggesting proteolysis ( Figure 3C ). Considering that both spike protein and albumin have molecular weights >60 kDa, it is likely that their release may be the result of similar filtration abnormalities. 34 Altogether, our data suggest that the presence of spike protein in urine samples of some COVID-19 patients may still be indicative of an unknown or unpredicted kidney injury, most likely spilling of spike protein from serum. Noteworthy, the presence of proteinuria and microscopic hematuria has been associated with greater clinical severity of COVID-19 disease. 20 The predominant form of kidney injury in COVID-19 seems to be acute tubular injury that might be secondary to cytokine storm or shock. Direct viral infection while present, may only occur in the most severe cases as noted in autopsy studies. [35] [36] [37] Another important finding of this study is the lack of viral RNA in the urine of most (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A significant finding in this study is that one child was found to have SARS-CoV-2 spike protein in the urine despite being negative by NP-PCR. Noteworthy, this urine sample was collected on the same day the NP swab was performed for qRT-PCR analysis. One possible explanation is that the child was previously infected and was tested negative due to viral clearance but continues to shed viral spike protein in the urine. Another possibility is that the NP-PCR in this case was a false negative. The ability of the antigen capture assay to detect spike protein in a NP-PCR-individual highlights the need for the development of assays that are not intrusive, are rapid and can be deployed for large scale detection of active infection in the general population and at different times, to prevent continued propagation of the virus. While urine ELISAbased tests are particularly suitable for large scale, repeat and rapid diagnostic campaigns, the fact that only 25% of infected individuals in our study were found to have spike protein in their urine suggests that the sensitivity of the current urine spikecapture assay is not sufficient for population-based screening. Efforts to evaluate the usefulness of this antigen-based assay to detect SARS-CoV-2 infection in other biospecimens such as saliva are warranted. In conclusion, our data demonstrate that 25% of SARS-CoV-2 infected individuals shed spike protein in the urine. qRT-PCR on urine samples demonstrated that this shedding is neither due to the presence of infected cells in this specimen nor to high levels of this viral protein in the serum. However, it does not preclude the possibility All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; https://doi.org/10.1101/2021.01.27.21250637 doi: medRxiv preprint of kidney infection by the virus. Nevertheless, our data highlight possible kidney abnormalities resulting from SARS-CoV-2 infection, the long-term consequences of which require further investigation. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. used as a cutoff across our study population. Multiple urine samples from the same All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 31, 2021. Fractional Excretion -Urine Urea U ELISA S1 pos U ELISA S1 neg p=0.88 Concentration of Spike Protein (ng/ml) S21 S18 S23 S42 S12 S17 S19 S24 S46 S26 S14 S1 S16 S2 S3 S22 S30 S5 S28 S4 S38 S40 S37 S6 S39 S7 S8 S41 S10 S9 S44 S45 S35 S11 S43 S31 S48 S49 S36 S47 S13 S29 S33 S27 S20 S34 S25 S32 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China A novel coronavirus outbreak of global health concern A Novel Coronavirus from Patients with Pneumonia in China Coronavirus disease 2019 (COVID-19) situation report-57. World Health Organization Estimating mortality from COVID-19 Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China Latest outbreak news from ProMEDmail: novel coronavirus --Middle East An update on the origin of SARS-CoV-2: Despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues The proximal origin of SARS-CoV-2 A pneumonia outbreak associated with a new coronavirus of probable bat origin Mechanisms of coronavirus cell entry mediated by the viral spike protein Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Associated with Rhabdomyolysis and Acute Kidney Injury (AKI) Caution on Kidney Dysfunctions Acute kidney injury in patients hospitalized with COVID-19 Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan Detecting microalbuminuria by urinary albumin/creatinine concentration ratio Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation Interpreting the fractional excretion of sodium Effect of reduced glomerular filtration rate on the fractional excretion of urea in the dg Fractional excretion of urea as a guide to renal dysfunction Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2 Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? Acute kidney injury 2016: diagnosis and diagnostic workup Impact of a new definition of acute kidney injury based on creatinine kinetics in cardiac surgery patients: a comparison with the RIFLE classification Creatinine kinetics and the definition of acute kidney injury Evaluation of rapid antigen test for detection of SARS-CoV-2 virus Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples Acute renal impairment in coronavirusassociated severe acute respiratory syndrome Mechanisms of glomerular albumin filtration and tubular reabsorption Spectrum of podocytopathies in newonset nephrotic syndrome following COVID-19 disease: a report of 2 cases Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology Covid-19 and kidney injury: Pathophysiology and molecular mechanisms A B